Home Mercks Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study
 

Keywords :   


Mercks Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study

2013-11-04 13:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Immunogenicity non-inferior to GARDASIL for original four HPV types Merck expects to file Biologics License Application with U.S. FDA in 2013 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the pivotal Phase III efficacy study, its investigational 9-valent HPV vaccine (V503) prevented approximately 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58. Language: English Contact: Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in additional study iii

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
04.11Natracare Launches E-Commerce Site
04.11Tropical Depression Eighteen Graphics
04.11The Honey Pot Launches Witch Hazel Intimate Wash & Wipes
04.11Remnants of Patty Graphics
04.11Tropical Depression Eighteen Forecast Discussion Number 4
04.11Remnants of Patty Forecast Discussion Number 10
More »